Survivorship Beyond Convalescence: 48-Month Quality-of-Life Outcomes After Treatment for Localized Prostate Cancer
|
|
- Susanna Richard
- 5 years ago
- Views:
Transcription
1 BRIEF COMMUNICATION Survivorship Beyond Convalescence: 48-Month Quality-of-Life Outcomes After Treatment for Localized Prostate Cancer John L. Gore, Lorna Kwan, Steve P. Lee, Robert E. Reiter, Mark S. Litwin Decision making for treatment of localized prostate cancer is often guided by therapeutic side-effect profiles. We sought to assess health-related quality-of-life outcomes for patients 48 months after treatment for localized prostate Men treated for localized prostate cancer (N = 475) were evaluated before treatment and at intervals during the 48 months after intervention. Changes in mean healthrelated quality-of-life scores and the probability of regaining baseline levels of health-related quality of life were compared between treatment groups. All statistical tests were two-sided. Urinary incontinence was more common after prostatectomy (n = 37) than after brachytherapy (n = 9) or external beam radiation therapy (n = 78) (both P <.), whereas voiding and storage urinary symptoms were more prevalent after brachytherapy than after prostatectomy (both P <.). Sexual dysfunction profoundly affected all three treatment groups, with a lower likelihood of regaining baseline function after prostatectomy than after external beam radiation therapy or brachytherapy ( P <.). Bowel dysfunction was more common after either form of radiation therapy than after prostatectomy. These results may guide decision making for treatment selection and clinical management of patients with health-related quality-of-life impairments after treatment for localized prostate J Natl Cancer Inst 9;: In 9, the immense public health burden of prostate cancer perseveres. Because no treatment has proven superiority in prostate cancer control, treatment side-effect profiles often determine treatment choices ( ). Prospective studies ( 2, 3 ) have characterized 2-year health-related quality-of-life outcomes among patients who were treated for clinically localized prostate cancer and have demonstrated treatment-specific impairments in urinary function, sexual function, and bowel function. Patient recovery profiles marked this 2-year period as one of convalescence. We hypothesized that the recovery documented in those prospective assessments would continue for surgical patients. Conversely, we hypothesized that the third and fourth years after radiation therapy would capture the onset of progressive functional decline as a result of cumulative radiation-induced injury. Herein, we describe the health-related quality-of-life outcomes for patients 48 months after treatment for localized prostate This analysis expands on previous work ( 2 ) that examined 2-year outcomes for patients treated for localized prostate cancer with radical prostatectomy (n = 37), external beam radiation therapy (n = 78), or brachytherapy (n = 9). Participant inclusion and exclusion criteria have been described previously ( 2 ). Briefly, subjects completed a comprehensive assessment of generic and prostate cancer specific healthrelated quality of life before treatment and completed follow-up questionnaires at, 2, 4, 8, 2, 8, 24, 3, 36, 42, and 48 months after treatment to capture maximal fluctuations in functional convalescence. All statistical tests were two-sided. Subjects who completed a 48-month survey were older (mean age ± SD = 63.7 ± 8. years) than those who did not (.2 ± 7. years) ( P <.); responders and nonresponders did not differ in other sociodemographic or clinical characteristics. We assessed generic health-related quality of life with the Medical Outcomes Study Short Form-36 ( 4 ), from which we derived physical and mental composite summary scores. The physical and mental composite scores measure generic, physical, and mental health and are standardized to the general US population with a normative mean of 5 and standard deviation of. Thus, a score of less than 5 denotes physical or mental function that is worse than the US average. We evaluated prostate cancer specific health-related quality of life with the University of California Los Angeles (UCLA) Prostate Cancer Index and the American Urological Association Symptom Index (AUASI) ( 5, 6 ). The Prostate Cancer Index quantifies urinary, sexual, and bowel dysfunction, with a higher score indicating better function. Conversely, higher scores on the AUASI indicate worse storage and voiding urinary symptoms. We examined mean scores over time and the subject s likelihood of regaining baseline function after treatment, as defined by a score within % of the baseline score. We modeled this binary outcome with nonlinear mixed models with random slopes and intercepts to evaluate the association between treatment modality and the likelihood of regaining baseline function. Other covariates were included in the models as fixed effects. In addition, we incorporated an interaction between treatment type and the duration of follow-up and between treatment type and the squared value of the duration of follow-up to control for the time dependence of functional recovery. Affiliations of authors: VA Greater Los Angeles Healthcare System Division of General Internal Medicine, Los Angeles, CA (JLG); UCLA Robert Wood Johnson Clinical Scholars Program, Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA Los Angeles, CA (JLG); Jonsson Comprehensive Cancer Center (LK, RER, MSL), Department of Urology (JLG, RER, MSL), and Department of Radiation Oncology (SPL), David Geffen School of Medicine at University of California, Los Angeles, (UCLA), Los Angeles, CA. Correspondence to: John L. Gore, MD, Robert Wood Johnson Clinical Scholars Program, University of California, Los Angeles, 9 Broxton Ave, 3rd Floor, Los Angeles, CA 924 ( jgore@mednet.ucla.edu ). See Funding and Notes following References. DOI:.93/jnci/djp4 The Author 9. Published by Oxford University Press. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org. 888 Brief Communication JNCI Vol., Issue 2 June 6, 9
2 Table. Demographic and clinical characteristics of the study sample (N = 475) * Characteristic Prostatectomy (n = 37) (n = 78) (n = 9) P value Mean age (±SD), y. ± ± ± 6.9 <. Race or ethnicity, No. (%).34 White 262 (85.3) 66 (84.6) 7 (78.9) Not white 45 (4.7) 2 (5.4) 9 (2.) Married or partnered, No. (%) 256 (83.4) 64 (82.) 72 (8.).75 Education level, No. (%).4 Less than college 8 (26.4) 22 (28.2) 36 (.4) College or more 223 (73.6) 56 (7.8) 53 (59.6) Comorbidity count, No. (%). 7 (38.) 22 (28.2) 3 (34.4) 9 (35.5) 32 (4.) 34 (37.8) 2 8 (26.4) 24 (3.8) 25 (27.8) Mean PSA level (±SD), ng/ml 7.3 ± ± ± 4.6 <. Mean biopsy Gleason 6.3 ± ±. 6.2 ±.8.2 score (±SD) Tumor stage, No. (%).3 T 26 (7.4) 42 (53.9) 7 (78.9) T2 9 (29.3) 34 (43.6) 7 (8.9) T3 (.) 2 (2.6) 2 (2.2) * = external beam radiation therapy; PSA = prostate-specific antigen. Categorical variables were compared with 2 analysis and Fisher exact test. Continuous variables were compared with independent samples t tests. All statistical tests were two-sided. After estimation, we calculated the interval probability of regaining baseline function from the model coefficients and created smoothed probability plots ( 7 ). All protocols were approved by the UCLA institutional review board and were compliant with the Health Insurance Portability and Accountability Act. Each participant provided written informed consent. Patients who underwent prostatectomy were younger, more highly educated, and had fewer comorbid conditions than those who underwent external beam radiation therapy or brachytherapy ( Table ). External beam radiation therapy patients had more aggressive tumor characteristics at baseline, with higher pretreatment mean levels of prostate-specific antigen and a higher prevalence of prostate cancers that were palpable on rectal examination (ie, stage classification T2 or greater) at presentation. Physical and mental well-being were largely unaffected by treatment for clinically localized prostate cancer ( Figures, A and B, and 2, A and B ). We identified a higher burden of storage and voiding symptoms among those who underwent brachytherapy than among those treated with external beam radiation therapy or radical prostatectomy ( P <.) ( Figures, C, and 2, C ). Although brachytherapy was associated with a lower likelihood of regaining baseline AUASI score than radical prostatectomy, the probability of regaining baseline function improved throughout the 48-month study period. Conversely, subjects who underwent external beam radiation therapy demonstrated progressive worsening of urinary function related to storage and voiding symptoms. Patients treated with either type of radiation therapy experienced minor impairments in urinary control ( Figures, D, and 2, D ); continence was most profoundly affected among prostatectomy patients ( P <.). After prostatectomy, the likelihood of continued functional recovery of continence beyond 3 months was low. Sexual dysfunction profoundly affected all three treatment groups ( Figures, E, and 2, E ). Patients treated with external beam radiation therapy suffered progressive decline in sexual function throughout the 48 months after treatment. Alternatively, patients treated with brachytherapy demonstrated continued, if slight, improvement in sexual function over time. Interpretation of sexual function outcomes among radical prostatectomy patients was confounded by their superior baseline mean scores. Despite better mean scores, the likelihood that prostatectomy patients would regain baseline sexual function remained minimal 4 years after surgery ( P <.). Patients who were treated with either type of radiation therapy reported more bowel dysfunction than prostatectomy patients ( Figures, F, and 2, F ). CONTEXT AND CAVEATS Prior knowledge In the absence of definitive results from randomized controlled clinical trials, treatment of localized prostate cancer is often selected by use of therapeutic side effects. Study design Questionnaire-based study of health-related quality-of-life outcomes for patients 48 months after treatment for localized prostate cancer that included prostatectomy, brachytherapy, or external beam radiation therapy. Questionnaires were completed before treatment and at different times during the 48 months after treatment. Contribution Urinary incontinence was more common after prostatectomy. Voiding and storage urinary symptoms were more common after brachytherapy. Sexual dysfunction profoundly affected all three treatment groups, with the lowest likelihood of regaining baseline function after prostatectomy. Bowel dysfunction was more common after either form of radiation therapy. Implications Results from this study provide information that can be used to select the best treatments for individual patients with prostate Limitations Patients may have undergone treatments that were discordant with preexisting conditions (eg, subjects treated with radiation therapy had worse bowel function scores at baseline, which grew worse with treatment). Subjects whose cancer recurred were not analyzed separately, which might have biased the results toward poorer outcomes. From the Editors Recovery from functional impairments followed a varied trajectory after treatment for clinically localized prostate Urinary dysfunction varied statistically and clinically significantly by treatment type. Incontinence was more common after surgery, but storage and voiding symptoms were more prevalent after radiation therapy. From initial postoperative trends in prospective assessments, other investigators have projected continued improvement in urinary control beyond 24 months after radical prostatectomy ( 2, 3 ). However, we found that urinary control recovery jnci.oxfordjournals.org JNCI Brief Communication 889
3 A. Physical composite score C. AUA symptom index E. Sexual function peaked 3 months after surgery. This finding may guide clinical decision making regarding the optimal timing of secondary therapies. Reassurance may assuage the worries of those with early impairments, but it will not suffice when the dysfunction persists. Depending on the severity of the dysfunction, patients and their clinicians may consider interventions ranging from behavioral modification to medication to urethral sling or artificial urinary sphincter. Incontinence was rare after radiation, consistent with previous analyses ( 2, 3, 8 2 ). We found pronounced exacerbation of storage and voiding urinary symptoms soon after brachytherapy, with substantial timedependent recovery to baseline levels. The continued improvement throughout our study refutes a previous report ( 3 ) documenting a flare in obstructive symptoms B. Mental composite score D. Urinary control F. Bowel function Time (Months): Sample size (No.) Figure. Longitudinal mean scores for health-related quality of life as measured by various instruments. A and B ) Medical Outcomes Study Short Form-36 physical and mental composite scores. Higher scores indicate better physical and mental health. C ) American Urological Association (AUA) Symptom Index. Higher scores indicate worse storage and voiding urinary symptoms. D F ) University of California Los Angeles Prostate Cancer Index. Higher scores indicate better urinary control, sexual function, or bowel function. = radical prostatectomy; = external beam radiation therapy. 8 among brachytherapy patients up to 2 years after treatment. After external beam radiation therapy, morbidity was initially mild, but urinary function worsened progressively beyond 24 months. Sexual dysfunction was common, regardless of primary treatment. Consistent with previous analyses, we identified a progressive decline in sexual function among patients treated with external beam radiation therapy ( 4, 5 ). Surprisingly, sexual function steadily improved among patients treated with brachytherapy. Thus, some aspect of the delivery of radiation therapy differentially affects the erectile nerves, with external beam radiation therapy inducing progressive permanent injury and brachytherapy causing initial dysfunction, but its effect was often transient. Although sexual function scores were higher among the prostatectomy cohort 2 months after surgery, the likelihood of prostatectomy subjects regaining baseline function, under a strict definition of return to baseline, remained minimal throughout the 48-month study period. Thus, a clinician may advise patients considering surgery that although they may be sexually functional, they almost certainly will not function exactly as they did before surgery. Finally, bowel dysfunction was more common among those undergoing external beam radiation therapy or brachytherapy. and external beam radiation therapy impaired bowel function equally. Other analyses ( 2, 6 ) of patient-derived assessments have corroborated the minimal impact of surgery on bowel function, with bowel dysfunction limited to those undergoing external beam radiation therapy or brachytherapy. Our results must be interpreted in the context of several potential limitations. Subjects may undergo treatment discordant with preexisting detriments in their health-related quality of life (eg, brachytherapy in men with severe baseline voiding urinary symptoms). In our sample, external beam radiation therapy and brachytherapy subjects had worse bowel function scores at baseline. These preexisting symptoms may have predisposed those who received either radiation modality to more severe bowel dysfunction after treatment. Concomitant with primary therapy, men who receive external beam radiation therapy or brachytherapy may have received androgen deprivation therapy. In our sample, hormone therapy was administered to 59% of subjects who received external beam radiation therapy and 23% of subjects who received brachytherapy. Those with more aggressive tumor characteristics more commonly receive androgen deprivation with radiation, which may impair both generic and disease-specific health-related quality of life ( 7, 8 ). Similarly, risk-stratified men may undergo brachytherapy with an external beam radiation therapy boost, which is known to confer worse health-related quality of life than either brachytherapy or external beam radiation therapy alone ( 8, 7, 9 ). Furthermore, we did not separately examine subjects whose cancer recurred, which also impacts both general well-being and cancer-specific domains ( 2, ). Inclusion of these subjects may 89 Brief Communication JNCI Vol., Issue 2 June 6, 9
4 A. Physical composite score have biased our sample toward worse outcomes. However, we sought to characterize long-term health-related quality of life after treatment for clinically localized prostate cancer, inclusive of factors inherent to the treatment choice. This method of analysis certainly introduces bias, but it also facilitates valid comparison of the expected outcomes of an average subject undergoing treatment for localized prostate We have characterized long-term health-related quality-of-life outcomes after treatment for clinically localized prostate Capturing baseline function before treatment permitted comparison of interval mean scores with pretreatment function. With assessments through 48 months after treatment, we encapsulated both the convalescent period immediately after therapy and the subsequent period B. Mental composite score C. AUA Symptom Index D. Urinary control E. Sexual function F. Bowel function characterized by functional improvement, functional plateau, or the onset of functional decline, depending on the primary therapy and the health-related quality-oflife domain assessed. These results may guide decision making for treatment selection and clinical management of patients with health-related quality-of-life impairments after treatment for localized prostate References Time (Months): Sample size (No.) Figure 2. Smoothed probability plots of the interval likelihood of returning to baseline healthrelated quality of life as measured by various instruments. A and B ) Medical Outcomes Study Short Form-36. C ) American Urological Association (AUA) Symptom Index. D F ) University of California Los Angeles Prostate Cancer Index. RTB = return to baseline; = radical prostatectomy; = external beam radiation therapy.. D Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 998 ; 28 ( ): Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 7 ; 9 ( ): Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 8 ; 358 ( 2 ): Ware JE Jr. SF-36 Health Survey: Manual and Interpretation Guide. New England Medical Center ; Boston, MA : The Health Institute ; Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 998 ; 36 ( 7 ): Barry MJ, Fowler FJ Jr, O Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 992 ; 48 ( 5 ): ; discussion Pinheiro JC, Bates DM. Approximations to the log-likelihood function in the nonlinear mixed-effects model. J Comput Graph Stat. 995 ; 4 ( ): Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol. ; 63 ( 3 ): Litwin MS, Pasta DJ, Yu J, Stoddard ML, Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. ; 64 ( 6 ): Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 4 ; 96 ( 8 ): Talcott JA, Rieker P, Clark JA, et al. Patientreported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 998 ; 6 ( ): Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2 ; ( 2 ): Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-25 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 3 ; 56 ( 4 ): Mantz CA, Nautiyal J, Awan A, et al. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am. 999 ; 5 ( 4 ): Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 999 ; 85 ( ): Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol. 4 ; 72 ( 2 ): jnci.oxfordjournals.org JNCI Brief Communication 89
5 7. Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG. Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology. 2 ; 59 ( 4 ): Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. Urology. 4 ; 63 ( 5 ): Speight JL, Elkin EP, Pasta DJ, et al. Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from CaPSURE. Int J Radiat Oncol Biol Phys. 4 ; ( 4 ): Miller DC, Sanda MG, Dunn RL, et al. Longterm outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 5 ; 23 ( 2 ): Funding California Department of Health Services V-27. Notes The funding organization had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. M. S. Litwin had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors have no financial disclosures and no conflicts of interest to report. The information contained in this manuscript was previously presented at the 8 American Urological Association Annual Meeting. Manuscript received November 9, 8 ; revised March 8, 9 ; accepted April 6, Brief Communication JNCI Vol., Issue 2 June 6, 9
Prostate Cancer Treatment for Economically Disadvantaged Men
Prostate Cancer Treatment for Economically Disadvantaged Men A Comparison of County Hospitals and Private Providers J. Kellogg Parsons, MD, MHS 1,2 ; Lorna Kwan, MPH 3 ; Sarah E. Connor, MPH 4 ; David
More informationUCLA PROSTATE CANCER INDEX Short Form (UCLA-PCI-SF), including the. RAND 12-Item Health Survey v2 (SF-12 v2)
UCLA PROSTATE CANCER INDEX Short Form (UCLA-PCI-SF), including the RAND 12-Item Health Survey v2 (SF-12 v2) HEALTH-RELATED QUALITY OF LIFE SCORING INSTRUCTIONS 1999 Mark S. Litwin, MD, MPH mlitwin@ucla.edu
More informationMORE THAN 140,000 men in the United States annually
Time Course and Predictors of Symptoms After Primary Prostate Cancer Therapy By James A. Talcott, Judith Manola, Jack A. Clark, Irving Kaplan, Clair J. Beard, Sonya P. Mitchell, Ronald C. Chen, Michael
More informationComiter CV (2002). "The male sling for stress urinary incontinence: a prospective study." J Urol 167(2 Pt 1):
Bacon, C. G., E. Giovannucci, et al. (2002). "The association of treatment-related symptoms with qualityof-life outcomes for localized prostate carcinoma patients." Cancer 94(3): 862-71. BACKGROUND: Most
More information10th anniversary of 1st validated CaPspecific
Quality of Life after Treatment of Localised Prostate Cancer Dr Jeremy Grummet Clinical Uro-Oncology Fellow May 28, 2008 1 Why? This is important May be viewed as soft science Until we know which treatment
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationPII S (01) CLINICAL INVESTIGATION
PII S3060-3016(01)01707-2 Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 3, pp. 614 623, 2001 Copyright 2001 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/01/$ see front
More informationRadical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life
Original Article JO et al. bju_5564.fm Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life YOSHIMASA JO, HIRATSUKA JUNICHI*, FUJII TOMOHIRO,
More informationIntroduction. Methods. Original Article: Clinical Investigation
International Journal of Urology (218) 25, 366--371 doi: 1.1111/iju.1353 Original Article: Clinical Investigation Impact of age on quality of life in patients with localized prostate cancer treated with
More informationLong- term quality of life after definitive treatment for prostate cancer: patient- reported outcomes in the second posttreatment decade
Cancer Medicine ORIGINAL RESEARCH Open Access Long- term quality of life after definitive treatment for prostate cancer: patient- reported outcomes in the second posttreatment decade Joanne W. Jang 1,2,
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationLong-Term Functional Outcomes after Treatment for Localized Prostate Cancer
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer Matthew J. Resnick, M.D., Tatsuki Koyama, Ph.D., Kang-Hsien
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More information2017 American Medical Association. All rights reserved.
Supplementary Online Content Borocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3
More informationERECTILE DYSFUNCTION AND SEXUAL PROBLEM 2-3YEARS AFTER PROSTATECTOMY AMONG AMERICAN, NORWEGIAN AND SPANISH PATIENTS
ERECTILE DYSFUNCTION AND SEXUAL PROBLEM 2-3YEARS AFTER PROSTATECTOMY AMONG AMERICAN, NORWEGIAN AND SPANISH PATIENTS Storås AH, Sanda MG, Garin O, Patil D, Chang P, Crociani C, Suarez F, Cvancarova M, Loge
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationABOUT MEN WILL BE
ORIGINAL CONTRIBUTION Comparison of ations by Urologists and Oncologists for Treatment of Clinically Localized Prostate Cancer Floyd J. Fowler, Jr, PhD Mary McNaughton Collins, MD, MPH Peter C. Albertsen,
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationUCSF UC San Francisco Previously Published Works
UCSF UC San Francisco Previously Published Works Title Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Permalink https://escholarship.org/uc/item/24j7405c
More informationDepartment of Urology, Cochin hospital Paris Descartes University
Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate
More informationImpact of radical perineal prostatectomy on urinary continence and quality of life: A longitudinal study of Japanese patients
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology919-81725 Blackwell Publishing Asia Pty LtdNovember 51211953958Original ArticleQuality of life after radical perineal prostatectomya Matsubara
More informationQuality of Life and Satisfaction Among Prostate Cancer Patients Followed in a Dedicated Survivorship Clinic
Original Article Quality of Life and Satisfaction Among Prostate Cancer Patients Followed in a Dedicated Survivorship Clinic Scott M. Gilbert, MD, MS 1,2 ; Rodney L. Dunn, MS 3 ; Daniela Wittmann, PhD
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationProspective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer
Sveistrup et al. Radiation Oncology (2016) 11:117 DOI 10.1186/s13014-016-0689-4 RESEARCH Open Access Prospective assessment of the quality of life before, during and after image guided intensity modulated
More informationQuality of life after high-dose-rate brachytherapy monotherapy for prostate cancer
ORIGINAL ARTICLE Vol. 41 (1): 40-45, January - February, 2015 doi: 10.1590/S1677-5538.IBJU.2015.01.07 Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer Jessika A. Contreras
More informationINTRODUCTION. Jpn J Clin Oncol 2006;36(4) doi: /jjco/hyl002
Jpn J Clin Oncol 2006;36(4)224 230 doi:10.1093/jjco/hyl002 Health-Related Quality of Life after Intensity Modulated Radiation Therapy for Localized Prostate Cancer: Comparison with Conventional and Conformal
More informationTREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME
ADULT UROLOGY TREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME VIBHA BHATNAGAR, SUSAN T. STEWART, WILLIAM W. BONNEY, AND ROBERT M. KAPLAN ABSTRACT
More informationMeasuring and Predicting Prostate Cancer Related Quality of Life Changes Using EPIC for Clinical Practice
Measuring and Predicting Prostate Cancer Related Quality of Life Changes Using EPIC for Clinical Practice Jonathan J. Chipman, Dana-Farber Cancer Institute Martin Sanda, Emory University Rodney L. Dunn,
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationTrajectories and Predictors of Symptom Occurrence, Severity, and Distress in Prostate Cancer Patients Undergoing Radiation Therapy
486 Journal of Pain and Symptom Management Vol. 44 No. 4 October 2012 Original Article Trajectories and Predictors of Symptom Occurrence, Severity, and Distress in Prostate Cancer Patients Undergoing Radiation
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationINTERNATIONAL JOURNAL OF ONCOLOGY 46: , 2015
INTERNATIONAL JOURNAL OF ONCOLOGY 46: 381-388, 2015 Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment
More informationTreatment of localized prostate cancer in elderly patients
Editorial Treatment of localized prostate cancer in elderly patients Mohammed Haseebuddin, Marc C. Smaldone Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA Correspondence
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationA comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,
More informationHealth-related Quality of Life After Primary Treatment for Localized Prostate Cancer: A Systematic Review of the Literature. Sara E.
Health-related Quality of Life After Primary Treatment for Localized Prostate Cancer: A Systematic Review of the Literature By Sara E. Wobker A Master's Paper submitted to the faculty of the University
More informationLONG-TERM POTENCY AFTER IODINE-125 RADIOTHERAPY FOR PROSTATE CANCER AND ROLE OF SILDENAFIL CITRATE
ADULT UROLOGY CME ARTICLE LONG-TERM POTENCY AFTER IODINE-125 RADIOTHERAPY FOR PROSTATE CANCER AND ROLE OF SILDENAFIL CITRATE RUPESH RAINA, ASHOK AGARWAL, KUSH K. GOYAL, CHERYL JACKSON, JAMES ULCHAKER,
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationQuality of Life After Modern Treatment Options for Prostate Cancer Ronald Chen, MD, MPH
Quality of Life After Modern Treatment Options I will be presenting some recently published data on the quality of life after modern treatment options for prostate cancer. My name is Dr. Ronald Chen. I'm
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationNomograms for prostate cancer
Review Article NOMOGRAMS FOR PROSTATE CANCER STEPHENSON and KATTAN There are several papers in this section on various aspects of prostate cancer: predictive models, robotic radical prostatectomy in large
More informationDose escalation with external beam therapy for
Rapid Communication Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationQuality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors Martin G. Sanda, M.D., Rodney L. Dunn, M.S., Jeff Michalski,
More informationDepartment of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.321 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.321&domain=pdf&date_stamp=2014-05-16
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationRacial variation in receipt of quality radiation therapy for prostate cancer
https://doi.org/10.1007/s10552-018-1065-5 BRIEF REPORT Racial variation in receipt of quality for prostate cancer Daniel J. Lee 1 Zhiguo Zhao 2 Li Ching Huang 2 Tatsuki Koyoma 2 Matthew J. Resnick 1 David
More informationClinical Study A Comparison of Radical Perineal, Radical Retropubic, and Robot-Assisted Laparoscopic Prostatectomies in a Single Surgeon Series
Prostate Cancer Volume 2011, Article ID 878323, 6 pages doi:10.1155/2011/878323 Clinical Study A Comparison of Radical Perineal, Radical Retropubic, and Robot-Assisted Laparoscopic Prostatectomies in a
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationSurvival outcomes for men in rural and remote NSW. Trend in prostate cancer incidence and mortality rates in Australia. The prostate cancer conundrum
7/8/20 7/8/20 Using PROMS to better understand prostate cancer outcomes: The NSW Prostate Cancer Care and Outcomes Study David Smith Research Fellow Cancer Research Division Monash Uni, 26 th June 20 Survival
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationActive Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists
Accepted Manuscript Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists Shearwood McClelland, III, MD, Kiri
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationQuality of life after prostate cancer treatments in patients comparable at baseline
FULL PAPER British Journal of Cancer (2013) 108, 1784 1789 doi: 10.1038/bjc.2013.181 Keywords: prostate cancer; side effects; toxicity; health-related quality of life; prostatectomy; radiotherapy Quality
More informationTilburg University. Published in: Journal of Endourology. Publication date: Link to publication
Tilburg University Health-related quality of life in I-125 prostate brachytherapy patients treated with and without volume-reducing hormone therapy Mols, Floortje; Stijns, P.; Dankaart, B.; Houterman,
More informationMODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT
MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationFinal published version:
Localized prostate cancer in Norway, the United States, and Spain: Between-country differences of variables before treatment among patients eligible for curative treatment Anne Holck Storås, The Norwegian
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More information5-YEAR URINARY AND SEXUAL OUTCOMES AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY
0022-5347/05/1735-1701/0 Reprinted from Vol. 173, 1701 1705, May 2005 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000154637.38262.3a 5-YEAR
More informationClinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate
Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationCombined Reporting of Cancer Control and Functional Results of Radical Prostatectomy $
European Urology European Urology 44 (2003) 656 660 Combined Reporting of Cancer Control and Functional Results of Radical Prostatectomy $ Laurent Salomon a,*, Fabien Saint a, Aristotelis G. Anastasiadis
More informationCyberKnife SBRT for Prostate Cancer
CyberKnife SBRT for Prostate Cancer Robert Meier, MD Swedish Radiosurgery Center Swedish Cancer Institute Seattle, WA 2017 ESTRO Meeting, Vienna Austria 5-year safety, efficacy & quality of life outcomes
More informationPROSTATE CANCER TREATMENT
PROSTATE CANCER TREATMENT INFORMATION GUIDE Several effective treatment options exist today for men diagnosed with prostate cancer. Each man s particular cancer, overall health, age, and lifestyle will
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationActive surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation
Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden
More informationThe Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer
55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert
More informationPatient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy
Patient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy James A. Talcott, Patricia Rieker, Kathleen J. Propert, Jack A. Clark, Kenneth I. Wishnow, Kevin R. Loughlin, Jerome
More informationRadiation Dose Escalation for Localized Prostate Cancer
Radiation Dose Escalation for Localized Prostate Cancer Intensity-Modulated Radiotherapy Versus Permanent Transperineal Brachytherapy William W. Wong, MD 1 ; Sujay A. Vora, MD 1 ; Steven E. Schild, MD
More informationThe introduction of serum prostate-specific antigen
ADULT UROLOGY CME ARTICLE COMPARING PSA OUTCOME AFTER RADICAL PROSTATECTOMY OR MAGNETIC RESONANCE IMAGING- GUIDED PARTIAL PROSTATIC IRRADIATION IN SELECT PATIENTS WITH CLINICALLY LOCALIZED ADENOCARCINOMA
More informationTanaka et al. BMC Cancer (2017) 17:573 DOI /s
Tanaka et al. BMC Cancer (2017) 17:573 DOI 10.1186/s12885-017-3565-1 RESEARCH ARTICLE Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated
More informationFactors Associated with Initial Treatment for Clinically Localized Prostate Cancer
Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting
More informationOncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting
END-2010-0305-ver9-Engel_1P.3d 09/17/10 2:42pm Page 1 END-2010-0305-ver9-Engel_1P Type: research-article JOURNAL OF ENDOUROLOGY Volume 24, Number 00, XXXX 2010 ª Mary Ann Liebert, Inc. Pp. &&& &&& DOI:
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationIrreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationRadiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities
Radiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities Prostate cancer is predominately a disease of older men,
More informationPSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up
Original article Original articles PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Roman Makarewicz, MD, PhD, Prof., Andrzej
More informationUnderstanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices
Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices Scott R. Hawken,* Paul R. Womble,* Lindsey A. Herrel, Zaojun Ye, Susan M. Linsell, Patrick M. Hurley,
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationInception Cohort. Center for Evidence-Based Medicine, Oxford VIP-- Inception Cohort (2008) Nov Dec
VIP-- Inception Cohort (28) Robotic Prostatectomy: Oncological and Functional Outcomes after 4 cases The Donald Smith Lecture Nov 2- Dec 28---- ----42 patients Patient 1 to patient 38 PSA follow-up -------3481
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationINTRODUCTION PATIENTS AND METHODS. Jpn J Clin Oncol 2007;37(10) doi: /jjco/hym098
Jpn J Clin Oncol 2007;37(10)775 781 doi:10.1093/jjco/hym098 Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected
More informationHIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
0022-5347/01/1663-0876/0 THE JOURNAL OF UROLOGY Vol. 166, 876 881, September 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED
More informationDate Modified: May 29, Clinical Quality Measures for PQRS
Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationRacial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study
ava ilable at www.sciencedirect.com journa l homepage: www.europea nurology.com Prostatic Disease Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results
More information